Fig 2: Comparison of maspin, ANXA3, LAP3, and PSMA1 expressions by IHC and Western blotting in 8 patientsNormal (N) and tumor (T) colon tissue pairs from 8 patients (CA1-CA8) are examined. Paired tissue were examined by IHC (normal tissue – dark blue; tumor tissue – dark red). Protein extracts were examined by Western blotting (normal – light blue; tumor – light red). Expressions were scored according to the average staining intensity on a 0-3 scale for IHC (left Y axis) and a 0-10 expression ratio scale for Western blotting (right Y axis), with normal tissue scaled to 1.

Fig 3: Differential expression of maspin, ANXA3, LAP3 and PSMA1 in colon cancer tissue validated by western blottingProtein extracts from 8 pairs of colon tumor (T1-8) and normal tissue (N1-8) were separated by SDS PAGE and blotted with commercial antibodies specific to each protein. Expression of ß-actin in each tissue protein extract was used as a control. The numbers under each pair of blots represent the relative expression ratios, with ratios <1, =1, >1 indicating decreased, unchanged, or increased expression in tumor cancer, respectively.

Fig 4: RAB31 expression was associated with PSMA1, and PSMA1 overexpression was associated with a worse prognosis. (A) Representative images of IHC staining of RAB31 and PSMA1 in gastric tumor and non‐tumor tissues. (B) PSMA1 mRNA level was assessed by TCGA database. (C and D) Overall survival analysis of GC patients with low versus high PSMA1 expression. Survival rate was calculated by Kaplan–Meier survival analysis (p < 0.001, log‐rank test). (E) Overall survival analysis of our GC patients with low versus high PSMA1 expression.